Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03713021 · ClinicalTrials.gov registry record · NA
TraceIT Tissue Marker to Mark the Primary Resection Bed Margins of Oropharyngeal Cancers
A NA study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT03713021 is a NA study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 27 participants.
The verdict
NCT03713021, a NA study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this research study is to look at how using an injectable marker called TraceIT can help with the radiation treatment planning process. TraceIT is a gel that dissolves in the body over time and can be injected and is visible on many types of images that can be used in the treatment planning process. If the exact edges of negative tumor margins can be marked before treatment planning, it is thought that the area receiving radiation can be more personalized, thus potentially reducing unnecessary radiation to areas that are cancer-free.
Interventions
- DEVICE TraceIT Tissue Marker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2021-02-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03713021
The ClinicalTrials.gov registry entry for NCT03713021 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TraceIT Tissue Marker is the first listed.
NCT03713021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03713021 about?
NCT03713021 is a clinical study titled "TraceIT Tissue Marker to Mark the Primary Resection Bed Margins of Oropharyngeal Cancers". The purpose of this research study is to look at how using an injectable marker called TraceIT can help with the radiation treatment planning process. TraceIT is a gel that dissolves in the body over time and can be injected and is visible on many types of images that can be used in the treatment pl...
What is the current status of trial NCT03713021?
This trial is currently terminated. It is a NA study. The enrollment target is 27 participants. The study started on 2019-05-15. Estimated completion is 2021-02-17.
What interventions are being tested in trial NCT03713021?
The interventions under investigation include: TraceIT Tissue Marker (DEVICE).
Who is sponsoring clinical trial NCT03713021?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.